Sarepta Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was USD 189.41 million compared to USD 143.92 million a year ago. Net loss was USD 48.14 million compared to USD 196.5 million a year ago. Basic loss per share from continuing operations was USD 0.6 compared to USD 2.5 a year ago. Diluted loss per share from continuing operations was USD 0.6 compared to USD 2.5 a year ago. For the nine months, revenue was USD 500.43 million compared to USD 394.96 million a year ago. Net loss was USD 296.8 million compared to USD 364.81 million a year ago. Basic loss per share from continuing operations was USD 3.72 compared to USD 4.7 a year ago. Diluted loss per share from continuing operations was USD 3.72 compared to USD 4.7 a year ago.